TY - JOUR
T1 - Ventilator-associated tracheitis in children
T2 - Does antibiotic duration matter?
AU - Tamma, Pranita D.
AU - Turnbull, Alison E.
AU - Milstone, Aaron M.
AU - Lehmann, Christoph U.
AU - Sydnor, Emily R.M.
AU - Cosgrove, Sara E.
N1 - Funding Information:
Potential conflicts of interest. A. M. M. has received grant support through his institution from Sage Products and BioMérieux. C. U. L. has received travel reimbursement for board membership from American Medical Informatics Association, has received payment for lectures from South Carolina Medicaid Association, and has received textbook royalties from Springer Verlag. All other authors: no conflicts.
PY - 2011/6/1
Y1 - 2011/6/1
N2 - Background. The optimal duration of antibiotic therapy for ventilator-associated tracheitis (VAT) has not been defined, which may result in unnecessarily prolonged courses of antibiotics. The primary objective of this study was to determine whether prolonged-course (≥7 days in duration) therapy for VAT was more protective against progression to hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), compared with short-course antibiotics (<7 days in duration). The secondary objective was to determine whether prolonged-course therapy was more likely to result in the acquisition of multidrug-resistant organisms (MDROs) compared with short-course therapy. Methods .We conducted a retrospective cohort study of children ≤18 years of age hospitalized in the intensive care unit and intubated for ≥48 h from January 2007 through December 2009 who received antibiotic therapy for VAT. Results .Of the 1616 patients intubated for at least 48 h, 150 received antibiotics for clinician-suspected VAT, although only 118 of these patients met VAT criteria. Prolonged-course antibiotics were not protective against subsequent development of HAP or VAP (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.40-2.91). Factors associated with subsequent MDRO colonization or infection included prolonged-course antibiotic therapy (HR, 5.15; 95% CI, 1.54-7.19), receipt of combination antibiotic therapy (HR, 3.24; 95% CI, 1.54-6.82), and days of hospital exposure prior to completing antibiotic therapy (HR, 1.08; 95% CI, 1.04-1.12). Conclusion s.A prolonged course of antibiotics for VAT does not appear to protect against progression to HAP or VAP compared with short-course therapy. Furthermore, prolonged antibiotic courses were associated with a significantly increased risk of subsequent MDRO acquisition.
AB - Background. The optimal duration of antibiotic therapy for ventilator-associated tracheitis (VAT) has not been defined, which may result in unnecessarily prolonged courses of antibiotics. The primary objective of this study was to determine whether prolonged-course (≥7 days in duration) therapy for VAT was more protective against progression to hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP), compared with short-course antibiotics (<7 days in duration). The secondary objective was to determine whether prolonged-course therapy was more likely to result in the acquisition of multidrug-resistant organisms (MDROs) compared with short-course therapy. Methods .We conducted a retrospective cohort study of children ≤18 years of age hospitalized in the intensive care unit and intubated for ≥48 h from January 2007 through December 2009 who received antibiotic therapy for VAT. Results .Of the 1616 patients intubated for at least 48 h, 150 received antibiotics for clinician-suspected VAT, although only 118 of these patients met VAT criteria. Prolonged-course antibiotics were not protective against subsequent development of HAP or VAP (hazard ratio [HR], 1.08; 95% confidence interval [CI], 0.40-2.91). Factors associated with subsequent MDRO colonization or infection included prolonged-course antibiotic therapy (HR, 5.15; 95% CI, 1.54-7.19), receipt of combination antibiotic therapy (HR, 3.24; 95% CI, 1.54-6.82), and days of hospital exposure prior to completing antibiotic therapy (HR, 1.08; 95% CI, 1.04-1.12). Conclusion s.A prolonged course of antibiotics for VAT does not appear to protect against progression to HAP or VAP compared with short-course therapy. Furthermore, prolonged antibiotic courses were associated with a significantly increased risk of subsequent MDRO acquisition.
UR - http://www.scopus.com/inward/record.url?scp=79957484754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79957484754&partnerID=8YFLogxK
U2 - 10.1093/cid/cir203
DO - 10.1093/cid/cir203
M3 - Article
C2 - 21540205
AN - SCOPUS:79957484754
SN - 1058-4838
VL - 52
SP - 1324
EP - 1331
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 11
ER -